Analyst Upgrades: Red Hat, Inc., Momenta Pharmaceuticals, Inc., and First Solar, Inc.

Analysts upwardly revised their ratings on Red Hat Inc (NYSE:RHT), Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), and First Solar, Inc. (NASDAQ:FSLR)

by Karee Venema

Published on Jun 19, 2015 at 9:36 AM
Updated on Jun 19, 2015 at 9:42 AM

Analysts are weighing in on software solution specialist Red Hat Inc (NYSE:RHT), biotechnology firm Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), and alternative energy issue First Solar, Inc. (NASDAQ:FSLR). Here's a quick roundup of today's bullish brokerage notes on RHT, MNTA, and FSLR.

  • RHT last night reported first-quarter earnings that beat analysts' estimates, and Wall Street responded in kind. Specifically, the stock received no fewer than eight price-target hikes, including one from Cantor Fitzgerald to $90 from $85. This represents expected upside of 12.5% to current trading levels. Amid this bullish backdrop, the shares are up 1.8% out of the gate at $79.98, and just tagged a fresh 15-year high of $80.46. Technically speaking, the security has now tacked on 15.6% year-to-date. Option traders, meanwhile, have been bracing for a pullback by buying to open puts over calls at a rapid-fire rate in recent months. In fact, Red Hat Inc's 50-day International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) put/call volume ratio of 0.56 ranks just 2 percentage points from a 52-week peak.

  • Biotechs have had a big week, and today, MNTA is in the spotlight. The stock is up 1.2% at $24.70 out of the gate, after the company's U.S. launch of its generic multiple sclerosis drug was met with upwardly revised price targets from Brean Capital (to $31) and Stifel (to $29). The equity has been on fire since hitting its year-to-date low of $10.22 in early February, more than doubling in value. Additionally, the stock tagged the $25.56 mark this morning -- its loftiest perch since July 2010. A continued rise may prompt short sellers to start throwing in the towel, which could spell additional gains for Momenta Pharmaceuticals, Inc. down the road. Nearly 17% of the security's float is sold short, representing six sessions' worth of pent-up buying demand, at average daily volumes.

  • FSLR is up 1.3% in early trading, after Needham upped its price target on the shares to $73 from $69. The brokerage firm cited the successful IPO of 8Point3 Energy Partners (CAFD) -- a yieldco formed between FSLR and SunPower Corporation (NASDAQ:SPWR) -- as the catalyst, saying CAFD is "uniquely positioned as a solar-only yieldco with joint sponsorships by two of the largest solar developers in the world." Separately, CAFD priced its IPO at $21 per share this morning. On the charts, the shares of FSLR have been gaining ground since bouncing in the $49 region last week, up more than 7% to trade at $52.64. Option traders have been rolling the dice on more upside, too. At the ISE, CBOE, and PHLX, for example, First Solar, Inc.'s 10-day call/put volume ratio of 5.29 rests in the 99th annual percentile. In other words, calls have been bought to open over puts with more rapidity just 1% of the time within the past year.

A Schaeffer's exclusive!

The Expert's Guide

Access your FREE trading earning announcements before it's too late!



NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories

Look Who's Going Bankrupt Next in America
Porter Stansberry is making a concerning prediction.
Netflix Stock Heading into Historically Bullish Quarter
NFLX's 10-day moving average has stepped up as support lately
Silver Lining for Struggling Ulta Beauty Stock
Historically, ULTA is one of the best stocks to own in the second quarter
Look Who's Going Bankrupt Next in America
Porter Stansberry is making a concerning prediction.